4//SEC Filing
ALLEN LEE F MD PhD 4
Accession 0001209191-19-056020
CIK 0001685071other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:32 PM ET
Size
11.5 KB
Accession
0001209191-19-056020
Insider Transaction Report
Form 4
ALLEN LEE F MD PhD
Chief Medical Officer
Transactions
- Disposition to Issuer
Common Stock
2019-11-12−9,635→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-11-12−10,000→ 0 totalExercise: $16.08Exp: 2029-07-29→ Common Stock (10,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-11-12−251,466→ 0 totalExercise: $3.73Exp: 2027-04-13→ Common Stock (251,466 underlying)
Footnotes (3)
- [F1]Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
- [F2]This option, which provided for vesting over a period of four years as follows: (i) 25% of the total shares subject to the option shall vest on April 14, 2018, and (ii) 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $5,977,346.82, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
- [F3]This option, which provided for vesting over a period of four years as follows: One-fourth (1/4th) of the shares vest July 30, 2020, and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter, was accelerated and canceled in the Merger in exchange for a cash payment of $114,200.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
Documents
Issuer
Dova Pharmaceuticals Inc.
CIK 0001685071
Entity typeother
Related Parties
1- filerCIK 0001408474
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 4:32 PM ET
- Size
- 11.5 KB